The JAK is currently licensed for use in RA are tofacitinib (JAK1/JAK3 inhibitor), baricitinib (JAK1/JAK2 inhibitor), upadacitinib (JAK1 inhibitor), and filgotinib (JAK1 inhibitor). The gene discussed is JAK2; the disease is rheumatoid arthritis.